The effect of long-term deafness on speech recognition in postlingually deafened adult CLARION cochlear implant users

Research suggests that duration of deafness prior to cochlear implantation affects postoperative speech recognition in adults. Duration of deafness usually is defined as the number of years between the onset of profound deafness and implantation. The purpose of this study was to examine the effects of duration of deafness--expressed as percentage of life with deafness--independent of age at implantation on postoperative speech recognition in adult postlingually deafened CLARION Multi-Strategy Cochlear Implant users. Speech recognition tests (CID sentences and NU6 words) were administered to 202 consecutively implanted adults preoperatively and at 3 and 6 months after initial device fitting. Patients implanted at a younger age and those with smaller percentages of their lives with deafness achieved the highest levels of short-term postoperative speech recognition. Patients who had been deaf for > or =60% of their lives demonstrated a slower rate of speech recognition improvement than those with shorter durations of deafness, but still continued to improve with increased implant experience.

Clinical trial of the CLARION cochlear implant in children

Preoperative and postoperative efficacy results are reported for the first 58 children with 18 months of implant experience in the United States. A within-subjects repeated-measures design was used to compare preoperative performance with hearing aids to postoperative performance with the CLARION Multi-Strategy Cochlear Implant. The results revealed significant improvement over time on all speech perception measures. Higher scores and faster rates of progress were demonstrated by the children who used oral communication compared to children who used total communication, especially older children. The overall results suggest higher levels of performance and more rapid progress in the development of listening skills than has been reported in previous clinical trials with children. The latter finding appears to be due to advances in implant technology and changes in the demographic characteristics of the study groups.

Phase I-II evaluation of rapid sequence tandem high-dose melphalan with peripheral blood stem cell support in patients with multiple myeloma

This study was designed to determine the maximum tolerated dose (MTD) of high-dose melphalan (HDM), with peripheral blood stem cell support, that could be given twice within 90 days to patients with multiple myeloma. Twenty patients received tandem HDM at 160, 180 or 200 mg/m2 and a total of 55 were treated at the estimated MTD of 200 mg/m2. Seventeen of 55 (31%) did not receive cycle 2; six because of low CD34+ cell yields, three because of severe (n = 1) or fatal toxicities (n = 2) and eight for other reasons. The median interval between doses for 38 patients was 70 days (range 41-225). Three of 55 patients (5%) died of treatment-related causes. In patients completing two cycles of HDM, at any dose level, the complete remission rate improved from 15% following cycle 1 to 55% following cycle 2. The probabilities of survival, event-free survival and relapse or progression at 18 months for the 55 patients treated at the MTD were 0.84, 0.76 and 0.20, respectively, with a median follow-up of 19 months (range 9-36) from mobilization chemotherapy. It was concluded that two cycles of HDM, 200 mg/m2, could be administered to approximately 70% of patients under the age of 66 with multiple myeloma in a median interval of 70 days, with improvement in CR rates.

Speech recognition performance of older children with cochlear implants

HYPOTHESIS

The primary purpose of this study was to determine if children, > or =5 years old, with onset of deafness before the acquisition of spoken language (i.e., prelingually deafened) derived more benefit from multichannel cochlear implants than from conventional hearing aids. It was hypothesized that children who used oral communication (speech plus listening) would demonstrate higher levels of performance after implantation than children who used total communication (English sign system plus speech and listening).

BACKGROUND

Previous research suggests that prelingually deafened children given implants at an older age derive limited benefit from these devices. Changes in candidacy criteria and advances in technology, however, may make cochlear implants a more viable treatment option for this group of patients.

METHODS

A repeated-measures design was to used to compare patients' preoperative performance with hearing aids to postoperative performance with the CLARION cochlear implant after 3 and 6 months of device use. Pre- and postoperative performance were analyzed separately for children who used oral and total communication.

RESULTS

Both groups of children (oral and total communication) demonstrated significant postoperative improvement on all outcome measures over time. Postoperative scores of the children who used oral communication were significantly higher than those of the children who used total communication on four of the five outcome measures.

CONCLUSIONS

Prelingually deafened children who do not receive cochlear implants until > or =5 years of age derive significant benefit from current implant devices compared with that obtained with conventional hearing aids. The greatest benefit is derived by children who use oral communication, with much more limited benefit demonstrated by children who use total communication.

Speech recognition performance of pediatric Clarion patients

OBJECTIVE

To evaluate the speech performance of children with the Clarion Multi-Strategy Cochlear Implant.

PATIENTS

Prelingually deafened children who had received the Clarion implant.

METHODS

The Spondee and Monosyllable Word Identification subtest of the Early Speech Perception test, the Glendonald Auditory Screening Procedure (GASP), and the Phonetically Balanced Kindergarten test (PB-K) were administered to subjects 3 and 6 months after implantation.

RESULTS

At 3 months, subjects' performance was higher than preoperatively with hearing aids. At 6 months, performance improved further. Scores were higher on the ESP and GASP than on the PB-K. The scores indicate better levels of speech recognition than were obtained with older implant processing strategies. Subjects varied considerably in their performance. The results are preliminary because of the small sample.

Use of a parent-report scale to assess benefit in children given the Clarion cochlear implant

OBJECTIVE

To assess the auditory skills in everyday situations of prelingually deafened children with Clarion cochlear implants compared with hearing aids used preoperatively.

STUDY DESIGN

The Meaningful Auditory Integration Scale (MAIS) was used to determine the preoperative and postoperative auditory skills of the children.

RESULTS AND DISCUSSION

After implantation, the children showed improvement in three skill areas: bonding to the device, spontaneous alerting to sound in everyday situations, and ability to derive meaning from sound in the environment.

Collection of peripheral blood progenitor cells after the administration of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor: an analysis of 497 patients

BACKGROUND

There is great interpatient variability in the number of peripheral blood stem cells collected, as measured by CD34+ cell content, after the administration of chemotherapy and a growth factor. The ability to predict patients who fail to yield adequate quantities of CD34+ cells would be of value. However, very few reports include large numbers of patients treated in an identical fashion.

STUDY DESIGN AND METHODS

Between 1991 and 1995, 497 consecutive patients with a variety of malignant diseases received cyclophosphamide (4 g/m2), etoposide (600 mg/m2), and granulocyte-colony-stimulating factor (6 micrograms/kg/day) for mobilization and collection of a target dose > or = 2.5 x 10(8) CD34+ cells per kg. Multivariate analyses were performed to determine the factors associated with failure to achieve this target harvest.

RESULTS

A median of 14.71 x 10(6) CD34+ cells per kg (range, 0.08-137.55) was harvested with a median of 2 (range, 1-11) apheresis procedures. Ninety-one percent of patients yielded > or = 2.5 x 10(5) CD34+ cells per kg. Patients with Stage II-III breast cancer, who had pretreatment platelet counts > or = 150 x 10(9) per L and patients who underwent < or = 1 prior chemotherapy regimen had improved CD34+ cell yields. However, most patients with adverse risk factors yielded > or = 2.5 x 10(6) CD34+ cells per kg.

CONCLUSION

A regimen of cyclophosphamide, etoposide, and granulocyte-colony-stimulating factor led to the successful collection of adequate numbers of CD34+ cells in most patients without excessive toxicity. These observations confirm previous reports that intense prior therapy adversely affects the quantity of CD34+ cells harvested. Pretreatment and posttreatment variables did not predict with any certainty the small fraction of patients who fail to yield > or = 2.5 x 10(6) CD34+ cells per kg via multiple apheresis procedures.

Delayed perception of cochlear implant stimulation in children with postmeningitic ossified cochleae

A possible complication of postmeningitic deafness is cochlear ossification. Reports of immediate response to electrical stimulation despite this ossification have been encouraging. This report discusses three children who initially failed to perceive stimulation from their Nucleus multichannel cochlear implants. These patients showed no behavioral responses to any of 10 to 20 electrodes inserted into their ossified cochleae, even at maximum stimulus levels (1750 microA). Stimulus-response behavior had been well documented prior to implantation and was not considered a factor in their failure to respond. These patients continued to wear the speech processors programmed at maximum stimulus/current levels. Eventually, all three patients began responding following 5 to 12 months of device use. These results suggest that continued use of electrical stimulation may result in eventual perception.

Feasibility of multichannel human cochlear nucleus stimulation

Bipolar electrical stimulation of the brainstem cochlear nucleus (CN) following acoustic tumor removal in an only-hearing ear can provide beneficial hearing. However, the benefits of multichannel stimulation have yet to be defined. Following removal of a second acoustic tumor in a patient with neurofibromatosis 2, a Nucleus mini-22 channel implant device was inserted with the electrode array tip from the foramen of Luschka cephalad along the root entry zone of the eighth nerve, secured by a single suture superficially in the brain stem. Initial stimulation on the sixth postoperative day indicated that electrodes 18 to 22 were capable of CN stimulation without seventh nerve stimulation. Presumed electrode migration precluded further CN stimulation 1 month later. This report illustrates the feasibility of brainstem CN stimulation with an existing multichannel system.

Late relapse of testicular cancer

The complete response (CR) rate of disseminated germ-cell tumors with current aggressive chemotherapy and surgical resection of localized residual disease is between 70%-80%. Most patients who relapse do so within the first year of therapy. We have observed seven patients with germ-cell tumors treated with a variety of modalities who relapsed after more than two years in CR (45-87 months). Five patients are alive after salvage therapy with follow-up too short to assess the durability of second remission. There were no features distinguishing late relapse patients from all patients treated with chemotherapy for germ-cell tumors. Follow-up in patients treated for germ-cell tumors with chemotherapy should be extended to five years before curability can be established.